Lexicon Pharmaceuticals Stock
Lexicon Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael S. Exton
- Employees
- 81
- Market cap
- $676 M
- IPO
- 07/04/2000
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded…
Lexicon Pharmaceuticals stock: price history
1D
-7.9%
1W
-9.5%
1M
-24.8%
6M
-18.7%
YTD
+32.2%
1Y
+3.4%
2Y
-20.4%
5Y
-75.3%
10Y
-90.9%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~84% stronger price swings than usual
Ask the agents about Lexicon Pharmaceuticals
Analyst assessment of Lexicon Pharmaceuticals
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
5
BUY
7
HOLD
2
SELL
0
STRONG SELL
14
TOTAL · Hold
As of: 11/05/2026
Lexicon Pharmaceuticals stock metrics
P/E
-10.11
P/B
3.81
EV/EBITDA
-13.3
RETURN ON EQUITY
-18.2%
NET MARGIN
-4,591.8%
DEBT/EQUITY
0.34
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
49.2%
FLOAT SHARES
218,981,091
AVG. DAILY VOLUME (30D)
2,905,347
Insider transactions (SEC)
DEBBANE RAYMOND
Amouyal Philippe
BARKER SAM L
Cheung Ivan
SOBECKI CHRISTOPHER J
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -7.9%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Lexicon Pharmaceuticals stock
What does Lexicon Pharmaceuticals do?
Lexicon Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael S. Exton, the company employs around 81 people.
The IPO was on 07/04/2000; the stock trades on NASDAQ under the ticker LXRX.
What do analysts say about Lexicon Pharmaceuticals stock?
14 analysts rate the stock, the consensus is Hold (as of 11/05/2026).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Lexicon Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 84% stronger than usual.
Does Lexicon Pharmaceuticals pay a dividend?
No, Lexicon Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Lexicon Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lexicon Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lexicon Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.